PC
ACHN

Passport Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Passport Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-36,104
Closed -$442K – 255
2014
Q4 		$442K Buy
+36,104
New +$441K 0.01% 151

Other funds holding ACHN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Passport Capital's ACHN Position: Q1 2015 in Review

Passport Capital sold out of Achillion Pharmaceuticals (ACHN) in Q1 2015, closing a stake of 36,104 shares — an estimated $442K sold.

Passport Capital first reported a position in ACHN in Q4 2014 and held it in 1 quarter. The position peaked at $442K in Q4 2014. 173 funds tracked by Wall St. Rank hold ACHN as of Q1 2015.

  • Passport Capital reported no remaining Achillion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Passport Capital sold 36,104 Achillion Pharmaceuticals shares in Q1 2015, an estimated $442K.
  • Passport Capital first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Passport Capital's Achillion Pharmaceuticals position peaked at $442K in Q4 2014.
  • 173 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2015.

Based on Passport Capital's 13F filing for Q1 2015, filed 15 May 2015.